Literature DB >> 25806306

An alternative way to initiate Notch1 signaling in non-small cell lung cancer.

Yi-Lin Yang1, David Jablons1, Liang You1.   

Abstract

Non-small cell lung cancer (NSCLC) cells activate Notch1 signaling to promote cell proliferation and facilitate their survival. It now emerges that endothelial Delta-like ligand 4 (Dll4) may mediate Notch1 activation and inhibit tumor cell growth.

Entities:  

Keywords:  Delta-like ligand 4 (Dll4); Notch signaling; non-small cell lung cancer (NSCLC)

Year:  2014        PMID： 25806306      PMCID： PMC4367706          DOI： 10.3978/j.issn.2218-6751.2013.12.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  20 in total

1.  Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.

Authors:  Nobuhiro Haruki; Keiko S Kawaguchi; Shannon Eichenberger; Pierre P Massion; Sandra Olson; Adriana Gonzalez; David P Carbone; Thao P Dang
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

2.  DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Authors:  Timothy Hoey; Wan-Ching Yen; Fumiko Axelrod; Jesspreet Basi; Lucas Donigian; Scott Dylla; Maureen Fitch-Bruhns; Sasha Lazetic; In-Kyung Park; Aaron Sato; Sanjeev Satyal; Xinhao Wang; Michael F Clarke; John Lewicki; Austin Gurney
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633

Review 3.  Targeting notch signaling pathway in cancer: clinical development advances and challenges.

Authors:  Naoko Takebe; Dat Nguyen; Sherry X Yang
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

Review 4.  Notch signaling in lung cancer.

Authors:  Paola Galluzzo; Maurizio Bocchetta
Journal:  Expert Rev Anticancer Ther       Date:  2011-04       Impact factor: 4.512

5.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 6.  The Notch signaling pathway as a mediator of tumor survival.

Authors:  Kathleen M Capaccione; Sharon R Pine
Journal:  Carcinogenesis       Date:  2013-04-12       Impact factor: 4.944

7.  Cross-talk between Notch and EGFR signaling in human breast cancer cells.

Authors:  Jianjian Dai; Daoxin Ma; Shaolei Zang; Dongmei Guo; Xun Qu; Jingjing Ye; Chunyan Ji
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

Review 8.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.

Authors:  Gavin Thurston; Irene Noguera-Troise; George D Yancopoulos
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

9.  Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.

Authors:  Nicholas J Wang; Zachary Sanborn; Kelly L Arnett; Laura J Bayston; Wilson Liao; Charlotte M Proby; Irene M Leigh; Eric A Collisson; Patricia B Gordon; Lakshmi Jakkula; Sally Pennypacker; Yong Zou; Mimansa Sharma; Jeffrey P North; Swapna S Vemula; Theodora M Mauro; Isaac M Neuhaus; Philip E Leboit; Joe S Hur; Kyunghee Park; Nam Huh; Pui-Yan Kwok; Sarah T Arron; Pierre P Massion; Allen E Bale; David Haussler; James E Cleaver; Joe W Gray; Paul T Spellman; Andrew P South; Jon C Aster; Stephen C Blacklow; Raymond J Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

10.  Clinical implications of DLL4 expression in gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Yoshikazu Uenosono; Hiroshi Okumura; Hiroshi Kurahara; Yasuto Uchikado; Tetsuro Setoyama; Yoshiaki Kita; Yuko Kijima; Yuka Nishizono; Akihiro Nakajo; Tetsuro Owaki; Shinichi Ueno; Shoji Natsugoe
Journal:  J Exp Clin Cancer Res       Date:  2013-07-30
View more
  4 in total

1.  Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Authors:  Shijing Wang; Hui Wen; Wenyi Fei; Yuhong Zhao; Yuqi Feng; Lu Kuang; Min Wang; Min Wu
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 5.942

2.  Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets.

Authors:  Mehrdad Pazhouhandeh; Fatemeh Samiee; Tahereh Boniadi; Abbas Fadaei Khedmat; Ensieh Vahedi; Mahsa Mirdamadi; Naseh Sigari; Seyed Davar Siadat; Farzam Vaziri; Abolfazl Fateh; Faezeh Ajorloo; Elham Tafsiri; Mostafa Ghanei; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

3.  Silencing of lncRNA XLOC_035088 Protects Middle Cerebral Artery Occlusion-Induced Ischemic Stroke by Notch1 Signaling.

Authors:  Miao Chen; Feng Wang; Hairong Wang
Journal:  J Neuropathol Exp Neurol       Date:  2021-01-01       Impact factor: 3.685

Review 4.  Roles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and Perspectives.

Authors:  Lixia Guo; Ting Zhang; Ying Xiong; Yanan Yang
Journal:  Dis Markers       Date:  2015-09-27       Impact factor: 3.434
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.